Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | GNPAT | O15228 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 2/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.44 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17424533 | 0.89 | GNPAT (0.46) | MMECA2CA4ACEGNPAT | |
| SCHEMBL8737694 | 0.87 | MME (0.44) | MMECA2CA4ACEGNPAT | |
| SCHEMBL9068766 | 0.86 | ACE (0.55) | MMEACE | |
| SCHEMBL11412632 | 0.86 | MME (0.58) | MMEFOLH1NAALAD2 | |
| SCHEMBL17277128 | 0.86 | ACE (0.65) | MMEACEFOLH1 | |
| SCHEMBL9068730 | 0.86 | ACE (0.55) | MMEACE | |
| SCHEMBL8380946 | 0.85 | MME (0.51) | MMECA2CA4ACEGNPAT | |
| SCHEMBL8380947 | 0.85 | MME (0.51) | MMECA2CA4ACEGNPAT | |
| SCHEMBL15828303 | 0.85 | NAALAD2 (0.58) | MMEGNPATFOLH1NAALAD2 | |
| SCHEMBL24120786 | 0.83 | MME (0.47) | MMECA2CA4ACEGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114973-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090186351-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186351-A1 | NUCLEOTIDE ANALOGS | NT5C3B, RNGTT, NT5C2 | MME 651/4885CA2 4723/4885CA4 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.